GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s share price fell 0.7% on Friday . The stock traded as low as $31.37 and last traded at $31.50. 902,270 shares changed hands during mid-day trading, an increase of 1,758% from the average session volume of 48,553 shares. The stock had previously closed at $31.71.
GENMAB A/S/S Trading Down 0.7%
The company has a 50-day moving average of $30.76 and a 200-day moving average of $26.45.
About GENMAB A/S/S
Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.
Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.
See Also
- Five stocks we like better than GENMAB A/S/S
- Where Do I Find 52-Week Highs and Lows?
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- What Investors Need to Know About Upcoming IPOs
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- How is Compound Interest Calculated?
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
